Resveratrol improves the lipid profile promoted by red yeast rice (monacolin k) in patients with moderate dyslipidemia: An open-label, randomized, parallel-group controlled clinical trial

1. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5:493-506.10.1038/nrd206016732220Search in Google Scholar

2. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health--a comprehensive review of human clinical trials. Mol Nutr Food Res. 2011; 55:1129-41.10.1002/mnfr.20110014321688389Open DOISearch in Google Scholar

3. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Das DK, Delmas D, Gottfried C, Lin HY, Ma QY, Mukhopadhyay P, Nalini N, Pezzuto JM, Richard T, Shukla Y, Surh YJ, Szekeres T, Szkudelski T, Walle T, Wu JM. What is new for an old molecule?. Systematic review and recommendations on the use of reesveratrol. PLoS One. 2011; 6(6):e19881.10.1371/journal.pone.0019881311682121698226Search in Google Scholar

4. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011; 2;14:612-22.10.1016/j.cmet.2011.10.002388086222055504Open DOISearch in Google Scholar

5. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting Camp phosphodiesterases. Cell. 2012; 3;148:421-33.10.1016/j.cell.2012.01.017343180122304913Search in Google Scholar

6. Das S, Lin HS, Ho PC, Ng KY. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res. 2008; 25:2593-600.10.1007/s11095-008-9677-118629618Open DOISearch in Google Scholar

7. Subramanian L, Youssef S, Bhattacharya S, Kenealey J, Polans AS, van Ginkel PR. Resveratrol: challenges in translation to the clinic-- a critical discussion. Clin Cancer Res. 2010; 15;16:5942-8.10.1158/1078-0432.CCR-10-1486305744521045084Open DOISearch in Google Scholar

8. Bernard Fioretti, Roberto Spogli, Michele Sisani, Luana Perioli, Loredana Latterini. Co-precipitate of one or more stilbene polyphenols and their derivatives in lamellar anionic solids, it’s applications and related preparation method EP 2679243 A1.Search in Google Scholar

9. Fung WT, Subramaniam G, Lee J, Loh HM, Leung PH. Assessment of extracts from red yeast rice for herb-drug interaction by in-vitro and in-vivo assays. Sci Rep. 2012;2:298.10.1038/srep00298329188122389767Search in Google Scholar

10. Li Y, Jiang L, Jia Z, Xin W, Yang S, Yang Q, Wang L. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One. 2014; 4;9:e98611.10.1371/journal.pone.0098611404558024897342Search in Google Scholar

11. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006, EFSA Journal 2011; 9:2304.Search in Google Scholar

12. McAloon CJ, Boylan LM, Hamborg T, Stallard N, Osman F, Lim PB, Hayat SA. The changing face of cardiovascular disease 2000-2012: An analysis of the world health organization global health estimates data. Int J Cardiol. 2016; 1;224:256-264.10.1016/j.ijcard.2016.09.02627664572Search in Google Scholar

13. Alberti KG, Zimmet P. The metabolic syndrome: time to reflect. Curr Diab Rep. 2006; 6:259-61.10.1007/s11892-006-0057-016879776Search in Google Scholar

14. Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des. 2013;19 (34):6064-93.10.2174/13816128113199990407378269523448440Search in Google Scholar

15. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011 Nov 2;14(5):612-22.10.1016/j.cmet.2011.10.002388086222055504Open DOISearch in Google Scholar

16. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention.; Hational Heart, Lung, and Blood Institute.; American Heart Association.; World Heart Federation.; International Atherosclerosis Society.; International Association for the Study of Obesity.. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 20;120:1640-5.10.1161/CIRCULATIONAHA.109.19264419805654Search in Google Scholar

17. Pedro-Botet J, Millan Nunez-Cortes J, Chillaron JJ, Flores-Le Roux JA, Rius J. Severity of statin-induced adverse effects on muscle and associated conditions:data from the DAMA study. Expert Opin Drug Saf. 2016, 24:1-5.Search in Google Scholar